The anti-CD25 immunotoxin RFT5.dgA was constructed by coupling the monoclonal antibody RFT5 via a sterically hindered disulfide linker to deglycosylated ricin A-chain and was administered to patients with relapsed Hodgkin's lymphoma in four bolus infusions over 7 days (day 1, 3, 5 and 7). The maximum tolerated dose in these patients as defined in a previous phase I study was 15 mg/m 2 . Subsequently, further patients were enrolled at the maximum tolerated dose and a total of 18 patients were treated at this level. All patients had signs of progressive disease and were heavily pretreated. Sideeffects in this trial were moderate and related to vascular leak syndrome. Five of 18 patients experienced NCI grade III toxicities including weakness, edema, dyspnea, and myalgia. Eleven of 16 (69%) patients receiving two or more cycles produced human anti-ricin antibodies and human anti-mouse antibodies (у1.0 g/ml). Seventeen of 18 patients were evaluable for clinical response. These included two partial remissions. One patient demonstrated minor response and five patients stable diseases. We conclude that RFT5.dgA is of moderate clinical efficacy in this group of heavily pretreated refractory patients. Leukemia (2000) 14, 129-135.
Introduction
Although polychemotherapy and extended field radiotherapy have improved the remission rates of Hodgkin's lymphoma (HL) from less than 5% in 1963 to about 80% at present, 1 30-50% of patients with advanced stages at diagnosis finally succumb to the disease. 2 Data from other malignancies including colorectal cancer, 3 myeloid leukemia, 4 and nonHodgkin's lymphoma (NHL) 5 indicate that small numbers of residual tumor cells which remain after first-line treatment are the major source of relapse. Along these lines, recent data show that residual tumor cells in Hodgkin's patients can survive standard therapy and cause relapse. 6, 7 Thus, the elimination of residual tumor cells after first-line treatment might improve the outcome in HL.
Several approaches are available for eliminating residual tumor cells, including T cell stimulation, vaccination or selective destruction using monoclonal antibodies (Moabs) or Moab-based conjugates. 8, 9 Since no effective naked Moabs have been selected against Hodgkin/Reed-Sternberg (H-RS) cells thus far, 10 conjugates consisting of a specific cell-binding moiety and a potent toxin have been constructed. These immunotoxins (ITs) are ideally suited for eliminating residual tumor cells in HL for several reasons: (1) H-RS cells express surface antigens such as CD15, 11 IRac, 12 CD30, 13 CD25, must be killed is relatively small (Ͻ1% of lymphoid cells). (3) Tumors are well vascularized, permitting access to the IT. (4) The mechanism of cell destruction by ITs is different from that of conventional agents, thus circumventing drug resistance. (5) ITs are capable of killing dormant non-dividing cells. The two lymphoid activation markers CD25 and CD30 have attracted interest as targets for ITs in HL. Our group has evaluated most Moabs available against CD25 and CD30 in terms of their ability to form ricin A-chain ITs for possible clinical use in HL. 17 The ITs have been constructed by linking the antibody moiety via a sterically hindered linker (SMPT) to deglycosylated ricin-A (dgA). The most effective IT in preclinical studies was the anti-CD25 IT RFT5.dgA. CD25 is the ␣-chain of the IL-2 receptor (IL-2R). 18 This 55 kDa glycoprotein is not expressed on resting lymphocytes and stem cells but is efficiently induced following T cell activation. IL-2 receptors have been detected in high levels on cells in autoimmune disorders and on malignant cells in different hematopoietic malignancies. 19 Strauchen and Breakstone 20 were the first to demonstrate strong staining of H-RS cells in the majority of patients with HL using Moabs against CD25.
RFT5.dgA inhibited the protein synthesis of Hodgkinderived L540 cells by 50% at a concentration (IC 50 ) of 7 × 10 −12 M, which is identical to that of native ricin under the same experimental conditions. Impressive anti-tumor activity of this IT was demonstrated in nude mice with subcutaneously growing solid HL 21 and in SCID mice with disseminated human HL. 22 Furthermore, the binding of RFT5 to cryostat sections showed no major cross-reactivities with any normal human tissues other than a minority of cells in lymphoid tissue where a few large cells in tonsils and lymph nodes were stained. Thus, RFT5.dgA was selected for an FDA-approved clinical phase I trial in 15 patients with refractory HL. 23 Sideeffects observed were related to vascular leak syndrome (VLS), ie decreases in serum albumin, edema, weight gain, hypotension, tachycardia, dyspnea, myalgia, and weakness. The maximal tolerated dose (MTD) was defined at 15 mg/m 2 . Here, we report the results of a subsequently conducted trial involving 18 patients with refractory HD treated at MTD. Responses in this group of 17 evaluable heavily pretreated patients included two partial remissions (PRs), one minor response (MR), five stable disease (SD) and nine progressive disease (PDs).
Patients and methods

Patients
Eighteen patients with a histologically confirmed diagnosis of HL were enrolled in this trial and subsequently treated at the University of Cologne, at the Klinikum Chemnitz, and the Georg-August-University of Goettingen, Germany. All patients were refractory to conventional therapy or had a minimum of two relapses with evidence of progressive disease. To be eligible, adult patients had to have measurable disease, a Karnofsky performance status of at least 50%, a life expectancy of at least 3 months, creatinine <2.0 mg/100 ml, albumin >75% of the lower limit of normal, and a cardiac ejection fraction of у35%. In addition, more than 30% of the H-RS cells had to be positive for the CD25 antigen if a tumor biopsy was feasible. Exclusion criteria were uncontrollable infectious disease, collagen vascular disease, vasculitis, active second malignancy, chemotherapy or radiotherapy within 4 weeks, significant impairment of pulmonary function, granulocytes Ͻ1500/l, platelets Ͻ20 000/l or any other major organ dysfunction unrelated to HL, pregnancy, and presence of human anti-mouse antibodies (HAMA) or human anti-ricin antibodies (HARA) Ͼ1 g/ml. Concomitant administration of steroids was permited if patients had been treated with steroids for at least 4 weeks prior to study entry.
IT
The IT, RFT5.dgA, was prepared as described previously 24 by coupling deglycosylated ricin A-chain (dgA) (Inland Laboratories, Austin, TX, USA) via the heterobifunctional crosslinker SMPT (Pierce, Rockford, IL, USA) to the murine Moab RFT5 (IgG1) which recognizes the ␣-chain (CD25) of the IL-2 receptor. The IT was formulated as a sterile solution at 0.5 mg/ml in 0.85% NaCl containing 5 mM lysine. Vials containing 5, 10 or 20 ml were frozen and maintained at −80°C. Before use, the IT was filtered through a 0.22 m filter.
Protocol design and regimen
RFT5.dgA was administered intravenously (i.v.) in 100 ml isotonic saline over 4 h. The calculated total dose of the IT for one cycle of treatment was divided by four and administered on days 1, 3, 5 and 7. All patients were treated with 15 mg/m 2 /cycle, which was the MTD. Retreatment should be started on study day 15.
The study design was in accordance with the declaration of Helsinki. This trial was approved by the Ethic Committees of the University of Cologne and the University of Texas, Southwestern Medical Center, and performed under Food and Drug Administration Investigational New Drug application (IND No. 4989). Before treatment, all patients gave written informed consent. Size and duration of the trial was planned according to Simon's optimal two-stage design. 25 Target activity of interest (p1) was specified with 0.4 and a lower activity level (p0) with 0.2. Providing a probability у0.9 of rejecting a drug worse than p0 and probability у0.9 of notrejecting drugs better than p1. Thus, at the end of the first stage 3/17 responses must have been observed.
Pathology and eligibility
Biopsies of peripheral lymph nodes or involved organs were used to analyze the expression of CD25 (RFT5, 2A3) and CD30 (Ber-H2) on H-RS cells. CD30 staining was performed by using the anti-streptavidin-biotin-complex (ABC) method. Staining for the CD25 antigen was performed by using cryostat sections (ABC method, RFT5) or paraffin-embedded sections using the immunomax method (2A3; Becton Dickinson, Mountain View, CA, USA). 26 
Assessment of toxicity
Adverse events were graded according to the National Cancer Institute (NCI) Common Toxicity criteria as grade I (asymptomatic, easily tolerated), II (mild, tolerable), III (moderate, poorly tolerated) or IV (severe, life threatening). VLS was specifically graded as described elsewhere. 27 In brief, grade I was defined as minimal ankle pitting edema, grade II as ankle pitting edema and weight gain Ͻ7 kg, grade III as peripheral edema and weight gain of 7-11.5 kg or pleural effusion without pulmonary dysfunction, grade IV as anasarca, pleural effusion or ascites with respiratory deficit or weight gain Ͼ11.5 kg, and grade V as pulmonary failure requiring mechanical ventilation assistance usually resulting in death.
Pharmacokinetics
To determine the levels of intact RFT5.dgA in the peripheral blood of the patients an ELISA was used as described previously. 23 Serum samples were obtained from six patients at 0, 4, 5, 6, 8, 12 and 24 h and from 12 patients 0, 4 and 24 h after the start of each infusion. Elimination half-lifes (t 1/2 ) and areas under the curve (AUC) were analyzed using the PKCALC program. 28 
Detection of HAMA and HARA
HAMA and HARA were measured as previously described. 29 
Evaluation of response
The staging procedure included clinical examination, routine blood analyses, chest X-ray, abdominal ultrasound, thoracic and abdominal CT scans, electrocardiogram, echocardiogram, and body plethysmography. Clinical staging was performed according to the Ann Arbor system. Clinical status and laboratory parameters were controlled before each cycle. Additional tumor evaluations were performed 28 to 35 days following the completion of treatment to document the duration of responses. Restaging, including CT scans of involved areas, was performed after the second cycle. WHO criteria for response were used. A minimum of two cycles was required to evaluate treatment efficacy unless there was rapid progression. Responding patients were eligible for retreatment if they had less than 1 g/ml HAMA and HARA prior to the next cycle of treatment. Follow-up observation of patients after treatment was performed regularly.
Statistical analysis
Demographics and disease characteristics were summarized for all patients using descriptive statistics. All end points were evaluated according to the method of Kaplan and Meier. Median survival times were calculated by the product limit method.
Results
Patients and tumor pathology
The demographic data of the 18 patients treated with RFT5.dgA are summarized in Table 1 . Most patients were heavily pretreated with a median of 3.5 different chemotherapies (range: 2-6) including high-dose chemotherapy and autologous bone marrow transplantation in 11/18. In addition, all but one patient (M2) had received extensive radiotherapy. Eight of 18 patients were primary resistant to therapy. Fifteen of 18 patients presented with advanced disease at study entry and 12 had B symptoms.
Pathology
In three of 18 patients, no biopsy material could be gained. The expression of the CD25 antigen on the H-RS cells ranged from 31 to 50% in eight patients, from 51 to 70% in 6/15 patients and more than 70% in only one patient. In contrast, 7/15 of these biopsies evaluable for CD30 staining demonstrated more than 70% positive H-RS cells; four patients had 51-70% positive H-RS cells, two patients showed a less pronounced staining (30-50%) and two patients demonstrated less than 10% positive staining for CD30.
Toxicity
Toxicity was generally moderate and therapy was well tolerated. The toxicity profiles are described in Table 2 . Five patients experienced a grade III NCI toxicity, including VLS, dyspnea, fatigue, and myalgia. There was no hematologic tox- 
Pharmacokinetics
In all patients the maximum concentration of IT (C max ) was reached at the end of the IT infusion returning to (or close to) baseline after 12 to 24 h. The C max varied from 2.1 to 7.9 g/ml (average: 5.4 g/ml) with a median half-life of 6.4 h (range: 4.0-10.5 h). The area under the curve (AUC) ranged from 16.8 to 72.2 mg × h/l (mean 52.8 mg × h/l). Possible reasons for the interpatient differences might be related to size and location of tumor masses, variability in CD25 expression on tumor cells and peripheral blood cells, and levels of soluble CD25 in the serum of the patients.
Measurement of HAMA and HARA
No patient developed HAMA or HARA greater than 1.0 g/ml after the first cycle, whereas 11/16 (69%) patients receiving two or more cycles produced HAMA and HARA greater than 1.0 g/ml.
Clinical response
Sixteen of 18 patients received two or more cycles and one patient demonstrated PD after the first cycle, thus 17 patients were evaluable for response. Overall, there were two PRs, one MR and five SDs. Nine patients showed progressive disease. Two patients (11.8%) achieved PRs lasting 2 and 25 months, respectively. The median time to progression of patients with PR, MR or SD was 142 days (range: 78-752 days, Figure 1 ). Survival time of all patients varied from 89 to 1429+ days (median: 694+ days), including eight patients who are still alive ( Figure 2 ). Patients with PD had a median survival time of 663+ days (4/9 patients alive) as compared to 778+ days (4/8 patients alive) of the other patients. Since clinical response did not fulfill the criteria of optimum two-stage design no further patients were included in this trial.
Discussion
The anti-CD25 ricin A-chain IT RFT5.dgA has demonstrated impressive preclinical efficacy against human HL in vitro as well as in mouse models. 21, 22 The MTD of RFT5.dgA as evaluated in a phase I trial was 15 mg/m 2 and dose-limiting toxicities (DLTs) were related to VLS. Based on these results we performed a subsequent trial with further patients treated at MTD. Overall, 5/18 treated patients experienced NCI grade III toxicities including VLS, fatigue, edema, dyspnea and myalgia. Of the patients receiving two or more cycles of the IT, 69% (11/16) made HAMA and HARA (Ͼ1.0 g/ml). Clinical response included two PRs. One patient experienced MR, five patients SD and nine patients had PD. We conclude that RFT5.dgA is of moderate clinical effectivity in this group of heavily pretreated patients.
Response rate, side-effects, and pharmacokinetic parameters of the IT used in the present trial in patients with refractory HL are comparable to those observed with similar ricin A-chain containing ITs against NHL. Vitetta et al 29 reported 5/14 PRs in patients with relapsed NHL treated with an identical schedule (4-h bolus infusion every second day over 7 days) of the anti-CD22 IT, FabЈ-RFB4.dgA. Using the IgG immunoglobulin as ligand (IgG-RFB4-dgA), one CR and five PRs occurred in 24 evaluable patients with relapsed NHL 30 when administered by the same schedule. In a subsequent phase I trial, RFB4.dgA was given as continuous infusion over 8 days with comparable clinical results (4/18 PR) and toxicity. 27 Stone and colleagues 31 compared bolus vs continuous . Peak serum concentrations of the IT at MTD and toxicity profile were similar, suggesting no advantage for a continuous infusion protocol of IgG-based ricin A-chain ITs. However, bolus infusion is less expensive and more convenient.
A recent analysis of all patients treated in clinical phase I/II protocols suggests that the continuous infusion of ricin Achain ITs is more often associated with treatment-related severe adverse events in patients with prior irradiation (P = 0.034) (Sausville and Vitetta, unpublished) . In these trials, DLT was always related to VLS consisting of decreased serum albumin, weight gain, edema, pulmonary edema and aphasia. These side-effects were also detected in the present trial as well as in the prior phase I. In contrast to the trials in NHL patients, however, we observed neither major pulmonary edema nor aphasia related to VLS. The dose-limiting side-effects were VLS, myalgia, dyspnea (without pulmonary effusion) and severe fatigue. Five of 18 patients treated at MTD experienced a grade III toxicity, but one patient receiving intensive irradiation 3 months before had to interrupt treatment. The younger age of our patients (mean: 29 years) might at least in part explain these differences when compared with the older (50-60 years) patients in the NHL trials.
The development of HAMA and HARA is a problem in most clinical trials rendering the IT ineffective. 32 In the present trial, 11/16 patients receiving more than one cycle of IT produced HAMA and HARA. Thus, development of antibodies appears limiting for further treatment. This might be circumvented by the use of humanized 33 or recombinant constructs with human ligands 34 or toxins. 35 Recombinant diphtheria toxin (DT) fusion proteins directed against the IL-2 receptor are currently being evaluated in clinical trials in patients with hematologic malignancies including CLL, 36 adult T cell leukemia, 37 Szezary's syndrome, 38 and other non-Hodgkin's lymphomas. 39 Patients with HL have been treated with recombinant fusion toxins such as DAB 389 IL-2 or DAB 486 IL-2 which are composed of a deletion mutant of diphtheria toxin (DAB) and IL-2. 40 LeMaistre et al 41, 42 conducted two studies with DAB 486 IL-2 in hematologic neoplasia expressing the IL-2 receptor without clinical response in four patients with HL. In contrast, one CR lasting more than 2 years in 1/4 HL patients was achieved with DAB 486 IL-2. 43 LeMaistre and colleagues 39 reported the results of a phase II trial with DAB 389 IL-2 in 73 patients with different lymphomas. None of 17 patients with HL responded. Fatigue was the dose-limiting toxicity. The disappointing data administering recombinant fusion toxins in HL might be due to a shorter half-life and lower cytotoxic potency of these constructs as compared to IgG-based ITs. Another possible explanation might be the expression of only the ␣-chain on H-RS cells without the other subunits forming the medium or high affinity IL2R which is required for uptake of IL-2.
The CD30 antigen is another strong candidate for selective immunotherapy in HL. Anti-CD30 ITs have been constructed by coupling the Moab Ber-H2 to Saporin-S6, a single-chain ribosome-inactivating protein (type 1 RIP). The Ber-H2/saporin IT was claimed to be superior to a BerH2 ricin Achain IT when compared under the same experimental conditions in vitro. 44 However, unconjugated free Saporin-6 had a 10 000-fold higher non-specific effect as compared to ricin A-chain. 21 In patients with advanced HL, Falini et al 45 demonstrated strong staining of nearly all H-RS cells on different tissue samples after i.v. application of 20-30 mg of the unconjugated BerH2. In a clinical trial involving four patients with refractory HL, 0.8 mg/kg Ber-H2-Sap6 was applied in one or two infusions over 4 h. Significant reduction in tumor mass was observed in 3/4 patients. Toxicity included fever, malaise, anorexia, fatigue, mild myalgias, weight gain, and a four-to five-fold increase in liver enzymes. A further eight patients were enrolled; 46 thus, 12 patients were treated overall. Four achieved PRs and three experienced MRs with a short median duration of 2 months.
Our group has conjugated several Moabs against CD30 to ricin A-chain 47 which were weaker both in vitro and in vivo when compared to RFT5.dgA. Recently, several new CD30 Moabs were reported 48 and evaluated as ricin A-chain ITs. Three ITs were more effective than their predecessors. The most potent new IT, Ki-4.dgA, was five times more effective in vitro than the previous most potent ITs, HRS-3.dgA and BerLeukemia H2-.dgA. Fifty percent of SCID mice bearing disseminated human HL showed continuous CRs when a single dose of Ki-4.dgA was administered. 49 Since Ki-4.dgA has no major crossreactivity with vital human organs, this IT is currently being evaluated in an ongoing phase I clinical trial. The examination of biopsy material of the patients reported here suggests that, as compared to the CD25 antigen, CD30 might be the better target due to stronger staining of tissue samples.
Therefore, future strategies should include the use of IT 'cocktails', ie a combination of ITs directed towards different antigens on a tumor cell. A 'cocktail' of two or more ITs against different antigens (CD25, CD30, IRac) on H-RS cells had superior effects when compared to the use of single ITs. 50 Similar superior effects have been reported using IT cocktails in vitro 51 and in SCID mice against non-Hodgkin's lymphoma. 52 A clinical trial in refractory NHL patients with continuous infusion of a combination of IgG-HD37.dgA (anti CD19) and IgG-RFB4.dgA (anti CD22) has been completed (Sausville and Vitetta, unpublished).
In conclusion, RFT5.dgA has demonstrated moderate efficacy at a dose with tolerable toxicity. Anti-tumor effects in this trial are comparable to other immunoconjugates administered to HL patients such as the recombinant DAB389-IL-2 fusion toxin or the bispecific Moab HRS-3/A9 directed against the CD30 and the CD16 antigen. 53 Problems associated with the IT used in this study are the distribution of CD25 in refractory HL, respectively, and the development of neutralizing antibodies in nearly 70%. The development of small recombinant (human) anti-CD30 ITs might circumvent these obstacles. 54, 55 Since clinical experience with ITs in advanced refractory Hodgkin's lymphoma is still very limited, future clinical trials should evaluate whether this new type of specific immunotherapy can be validated in HL patients with small tumor burdens after conventional therapy. Furthermore, RFT5.dgA might be more effective against CD25-positive entities such as T-CLL or cutaneous T cell lymphoma. 39 
